Nutra Pharma Corp.
3473 High Ridge Road
Boynton Beach
Florida
33426
United States
Tel: 954-509-0911
Fax: 877-895-5647
Website: http://www.nutrapharma.com/
Email: info@nutrapharma.com
About Nutra Pharma Corp.
Nutra Pharma Corporation is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. By bringing a solid business foundation to the Company's Biotech holdings, Nutra Pharma has the ability to accelerate business plans, streamline costs and bring products to the market or licensure in a time-effective manner.
Nutra Pharma currently has three holdings:
Key Management: Rik J Deitsch, Chairman of the Board; President and Chief Executive Officer Stanley J Cherelstein, Director; Principal Accounting Officer Stewart Lonky, MD, Director; Science Chairman Tanivir Khandaker, MD, Director; Partnerships and Acquisition Chairman Michael Doherty, Chairman of the Board
Last Updated: 11-28-05
157 articles about Nutra Pharma Corp.
-
Nutra Pharma Announces First Manufacturing Agreement
3/23/2022
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin®, Pet Pain-Away™,Equine Pain-Away™ and Luxury Feet™ in the over-the-counter pain management market and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus and Pain, is announcing their first agreement to act as a product formulator and contract manufacturer for an outside company, Avini Health.
-
Nutra Pharma Letter to Shareholders
1/18/2022
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter pain management market and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus and Pain, announced that the Company's Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company's website.
-
Nutra Pharma Provides Business and Compliance Updates
7/26/2021
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter pain management market and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus and Pain, provided updates on their plans and progress on improving Company transparency and public company compliance.
-
Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures
7/23/2021
Nutra Pharma Corporation announced that they have filed a new provisional patent to protect their intellectual property surrounding their development of nerve agent counter measures.
-
As 2019 enters its second half, BioSpace takes a look at some of the warning letters issued by the U.S. Food and Drug Administration to the biopharma industry.
-
FDA takes action against marketer of unapproved products claiming to treat addiction, chronic pain and other serious conditions
3/19/2019
The U.S. Food and Drug Administration posted a warning letter to Nutra Pharma Corp. for illegally marketing unapproved products labeled as homeopathic with claims about their ability to treat addiction and chronic pain, including pain associated with cancer, diabetes, shingles, fibromyalgia and other serious conditions.
-
Nutra Pharma Corporation Letter to Shareholders
1/3/2018
Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company.
-
Nutra Pharma Corp. Announcing Launch Of Luxury Feet
6/23/2017
-
Nutra Pharma Corp. Featured On Univision's Spanish-Language News Show: Primer Impacto
6/8/2017
-
Nutra Pharma Corp. Announces Collaboration With The University of Maryland Bioprocess Scale-Up Facility In Preparation Of Material For Phase II Studies
6/2/2017
-
Nutra Pharma Corp. Announces Collaboration With The International Security Group For Development Of Nerve Agent Counter Measures
5/26/2017
-
Nutra Pharma Corp. CEO Rik Deitsch Interviewed By Stockguru.com
3/15/2017
-
Global Small Caps Initiates Coverage On Nutra Pharma Corp.
2/23/2017
-
Nutra Pharma Corp. And Nyloxin Featured On NBC News-Miami
2/15/2017
-
Nutra Pharma Corp. Letter To Shareholders
12/27/2016
-
Nutra Pharma Corp. Announces Infomercial Campaign For Pet Pain-Away
11/16/2016
-
Nutra Pharma Corp. Announces Licensing And Marketing Agreement For Pet Pain-Away
11/11/2016
-
Nutra Pharma Corp. Announces Additions To The Board Of Directors And Management Team
8/16/2016
-
Nutra Pharma Corp. Letter To Shareholders
12/30/2015
-
Nutra Pharma Corp. (NPHC) CEO Featured In Exclusive QualityStocks Interview
12/17/2015